ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

(-)-ラパマイシン

Sirolimus

HCID 5284616
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
53123-88-9
標準SMILES
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
InChIKey
QFJCIRLUMZQUOT-HPLJOQBZSA-N
分子式
C51H79NO13
平均分子量
914.2 g/mol
単同位体質量
913.55514157

概要

Sirolimus is a macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent. It has a role as an anticoronaviral agent, a geroprotector, an antineoplastic agent, an immunosuppressive agent, an antibacterial drug, a mTOR inhibitor and a bacterial metabolite. It is a macrolide lactam, an ether, an organic heterotricyclic compound, a secondary alcohol, a cyclic ketone, a cyclic acetal and an antibiotic antifungal drug.

名称と識別子

優先名称
Sirolimus
IUPAC
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
現地名
(-)-ラパマイシン
英語名
Rapamycin
分子式
C51H79NO13
分子量
914.17

名称と別名

rapamycinSirolimus53123-88-9(-)-RapamycinRapamunerapalimusAY-22989WY-090217FYARROHYFTORNpc-12gAntibiotic AY 22989
名称をさらに表示
シロリムスラパマイシン(-)-ラパマイシン抗生物質AY-22989EZSOLUTION™ RAPAMYCINラパマイシン(異性体混合物)シロリムス 溶液ラパマイシン STREPTOMYCES HYGROSCOPICUS由来ラパマイシン(異性体混合物)【シロリムス】EZSolution™ ラパマイシンシロリムス (JAN)(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-ジヒドロキシ-12-[(2R)-1-[(1S,3R,4R)-4-ヒドロキシ-3-メトキシシクロヘキシル]プロパン-2-イル]-19,30-ジメトキシ-15,17,21,23,29,35-ヘキサメチル-11,36-ジオキサ-4-アザトリシクロ[30.3.1.04,9]ヘキサトリアコンタ-16,24,26,28-テトラエン-2,3,10,14,20-ペンタオン(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-ヘキサデカヒドロ-9,27-ジヒドロキシ-3-[(1R)-2-[(1S,3R,4R)-4-ヒドロキシ-3-メトキシシクロヘキシル]-1-メチルエチル]-10,21-ジメトキシ-6,8,12,14,20,26-ヘキサメチル-23,27-エポキシ-3H-ピリド[2,1-c][1,4]オキサアザシクロヘントリアコンチン-1,5,11,28,29(4H,6H,31H)-ペンタオンラパリムス

物性

構造計算による物性

XLogP
6
極性表面積
195 Ų
水素結合供与体数
3
水素結合受容体数
13
回転可能結合数
6
重原子数
65
形式電荷
0
複雑度
1,760

実験および物理化学的性質

Chemical ClassesBiological Agents -> Bacterial Toxins
DrugsPharmaceuticals -> Antibiotics
LipidsPolyketides [PK] -> Polyenes [PK06]
LogP · 2 件

log Kow = 4.81 /Estimated/

4.3

Color/FormColorless crystalline solid from ether
Solubility · 3 件

Sol in ether, chloroform, acetone, methanol, and DMF; very sparingly sol in hexane and petr ether.

In water = 9.9X10-5 mg/L at 25 °C /Estimated/

1.73e-03 g/L

Human Drugs · 5 件

Breast Feeding; Lactation; Milk, Human; Immunosuppressive Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine (Orphan designations)

FDA approved drugs -> Active ingredient

Animal DrugsFDA approved animal drugs -> Active ingredient
Boiling Point183-185
Melting Point

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 4.7% (2 of 43) of reports.

Danger

H341 (11.6%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]

P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 2 件

REACH registered substance: (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]-oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone (EC: 610-965-5)

Rapamycin: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazards Summary · 1 件

Emergency treatment: Tacrolimus and related agents; May cause tremors and seizures; Other adverse effects in treated patients include diarrhea, kidney injury, anemia, thrombocytopenia, rash, and hypertension. Acute overdoses of up to 120 mg are generally well tolerated in adults. [HSDB] May cause irritation; Targets the immune system; [MSDSonline]

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl sirolimus, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Special ReportsShitrit D et al; Role of Siroliumus, A Novel Immunosuppressive Drug in Heart and Lung Transplantation; Respir Med 98 (9): 892-7 (2004)

化学と産業

薬理情報

ATC Code · 6 件

L04AA10

S - Sensory organs

L - Antineoplastic and immunomodulating agents

L - Antineoplastic and immunomodulating agents

QC - Cardiovascular system

QL - Antineoplastic and immunomodulating agents

Protein BindingSirolimus is 92% bound to human plasma proteins, mainly serum albumin (97%), α1-acid glycoprotein, and lipoproteins.
Pharmacodynamics · 1 件

Sirolimus is an immunosuppressant drug with antifungal and antitumour effects. In animal models, sirolimus prolonged allograft survival following various organ transplants and reversed an acute rejection of heart and kidney allografts in rats. Upon oral administration of 2 mg/day and 5 mg/day, sirolimus significantly reduced the incidence of organ rejection in low- to moderate-immunologic risk renal transplant patients at six months following transplantation compared with either azathioprine or placebo. In some studies, the immunosuppressive effect of sirolimus lasted up to six months after discontinuation of therapy: this tolerization effect is alloantigen-specific. Sirolimus potently inhibits antigen-induced proliferation of T cells, B cells, and antibody production. In rodent models of autoimmune disease, sirolimus suppressed immune-mediated events associated with systemic lupus erythematosus, collagen-induced arthritis, autoimmune type I diabetes, autoimmune myocarditis, experimental allergic encephalomyelitis, graft-versus-host disease, and autoimmune uveoretinitis.

Mechanism of Action · 2 件

Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15. In target cells, sirolimus binds to the cytoplasmic receptor FK506-binding protein-12 (FKBP12), an immunophilin, to form an immunosuppressive complex. FKBP12-sirolimus complex binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, survival, mobility, and angiogenesis. mTOR regulates the downstream signalling pathways involved in cell survival, such as the phosphatidylinositol-3 kinase (PI3K)/Akt signalling pathway. Inhibition of mTOR leads to the suppression of cytokine-driven T-cell proliferation, thus the progression from the G1 to the S phase of the cell cycle is inhibited. Sirolimus also inhibits antibody production. _In vitro_, sirolimus and other mTOR inhibitors inhibit the production of certain growth factors that may affect angiogenesis, fibroblast proliferation, and vascular permeability. Lymphangioleiomyomatosis is a disorder that primarily affects the lungs. It is characterized by lung tissue infiltration, unregulated alveolar smooth muscle proliferation, and cystic destruction of parenchyma. Although infrequent, it occurs as a symptomatic pulmonary complication in tuberous sclerosis complex (TSC), which is an inherited disorder caused by mutations in TSC genes. Loss of functional TSC gene leads to the aberrant activation of the mTOR signalling pathway, resulting in cellular proliferation and release of lymphangiogenic growth factors. Sirolimus inhibits the activated mTOR pathway and proliferation of alveolar smooth muscle cell proliferation.

関連反応

22 件
反応記録を作成
HRID 2147 の反応式
HRID 2147反応物として
HRID 8740 の反応式
HRID 8740反応物として
HRID 57786 の反応式
HRID 57786反応物として
HRID 253681 の反応式
HRID 253681反応物として
HRID 253682 の反応式
HRID 253682反応物として
HRID 348783 の反応式
HRID 348783反応物として
HRID 406966 の反応式
HRID 406966反応物として
HRID 406967 の反応式
HRID 406967反応物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Sirolomus
Rapamycin/Sirolimus CAS 53123-88-9
Rapamycin from Streptomyces hygroscopicus,23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine, AY 22989, Sirolimus
RPM
BCAR2
CS-440
TRERF1
RAPARapammuneSILA 9268AW36ZG6FT64L04AA10NSC-226080sirolimusumCHEBI:9168

データベース識別子

CAS
53123-88-9
PubChem CID
5284616
DTXSID
DTXSID5023582
ChEMBL
CHEMBL413
ChEBI
CHEBI:9168
UNII
W36ZG6FT64
EC Number
610-965-5
183-185 °C
Optical RotationSpecific optical rotation at 25 °C for D (sodium) line = -58.2 deg (methanol)
Physical Description · 2 件

Colorless solid; [Merck Index]

Solid

物理化学的性質

融点
183 · 183-185°C
沸点
799.83 °C · 799.83°C (rough estimate)
比旋光度
25 · D25 -58.2° (methanol)
比重(密度)
1.0352 · 1.0352 (rough estimate)
蒸気圧
0.56 hPa · 0.56 hPa ( 20 °C)
屈折率
1.528 · 1.5280 (estimate)
闪点
87 °C · 87 °C
貯蔵温度
-20 °C · -20°C
溶解性
2 MM · エタノール:ソリュブル2MM
外見
解決
酸解離定数(Pka)
10.4 · 10.40±0.70(Predicted)
色
無色~黄色
水溶解度
50 mg/ml · 50 mg/ml DMSO または 25 mg/ml メタノールに溶解。エタノール、ジメチルスルホキシド、ジメチルホルムアミドに可溶。水に溶けません。
Merck
14 · 14,8114
安定性
2 · 購入日から2年間安定です。この DMSO またはエタノール溶液は、-20°C で 2 か月間保存できます。
InChIKey
QFJCIRLUMZQUOT-HPLJOQBZSA-N
CAS データベース
53123 · 53123-88-9(CAS DataBase Reference)

化学的性質

化学的特性White to Off-White Solid

Hazard Classes and CategoriesMuta. 2 (11.6%)

安全と保護具

Disposal Methods · 1 件

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

毒性情報

Treatment · 1 件

General supportive measures should be followed in all cases of overdose. Based on the low aqueous solubility and high erythrocyte and plasma protein binding of sirolimus, it is anticipated that sirolimus is not dialyzable to any significant extent. (L1712)

Interactions · 5 件

Because St. John's wort (hypericum perforatum) induces the activity of CYP3A4 and P-glycoprotein and sirolimus is a substrate of both, concurrent use of St. John's wort with sirolimus may result in decreased sirolimus concentrations.

/Concurrent use of sirolimus with tacrolimus/ may cause excess mortality, graft loss and hepatic artery thrombosis (HAT) in liver transplant patients, most cases of HAT occured within 30 days post-transplantation.

/Antibiotics such as: rifabutin or rifapentine; and anticonvulsants such as: carbamazepine, phenobarbital, or phenytoin/ may decrease sirolimus concentrations due to cytochrome p450 3A4 (CYP3 A4) isoenzyme induction.

Significant increases in sirolimus clearance occur when administered with rifampin due to CYP3A4 induction by rifampin; an alternative antibacterial agent with less enzyme induction potential should be considered.

For more Interactions (Complete) data for SIROLIMUS (11 total), please visit the HSDB record page.

Health EffectsIncreased susceptibility to infection, lymphoma, and malignancy; bronchial anastomotic dehiscence in lung transplant patients; decline in renal function in long-term combination of cyclosporine with Rapamune; proteinuria. (L1874)
Hepatotoxicity · 1 件

Serum enzyme elevations occur in a proportion of patients taking sirolimus, but the abnormalities are usually mild, asymptomatic and self-limiting, rarely requiring dose modification or discontinuation. Rare instances of cholestatic hepatitis have been reported with sirolimus use, but the clinical features of the clinically apparent liver injury due to this agent have not been well defined. Most published cases of liver injury attributed to sirolimus occurred in patients exposed to other potentially hepatotoxic agents or who have other underlying possible causes of the abnormalities such as sepsis, cancer or parenteral nutrition. Hepatic artery thrombosis has been reported to be more common with sirolimus therapy after liver transplantation, but this association is still controversial.

Adverse EffectsNeurotoxin - Other CNS neurotoxin
Exposure RoutesOral
Milk ConcentrationsIt is not known whether sirolimus is distributed in human breast milk. However, trace amounts of sirolimus is excreted in the milk of lactating rats.
Toxicity Summary · 1 件

Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

Signs and Symptoms · 1 件

The most common ( ≥ 30%) adverse reactions observed with Rapamune in clinical studies are: peripheral edema, hypertriglyceridemia, hypertension, hypercholesterolemia, creatinine increased, constipation, abdominal pain, diarrhea, headache, fever, urinary tract infection, anemia, nausea, arthralgia, pain, and thrombocytopenia. (L1874)

Human Toxicity Excerpts · 3 件

/SIGNS AND SYMPTOMS/ Grapefruit juice may inhibit CYP 3A4 enzymes, leading to decreased metabolism of sirolimus; must not be taken with or used to dilute sirolimus.

/CASE REPORTS/ Cases of bronchial anastomotic dehiscence, most of which were fatal, have been reported in de novo lung transplant patients who received sirolimus in combination with other immunosuppressants. Because safety and efficacy of sirolimus as immunosuppressive therapy in lung transplant patients have not been established, such use in not recommended by the manufacturer.

/CASE REPORTS/ Use of sirolimus in combination with other immunosuppressants (i.e., cyclosporine, tacrolimus) has been associated with an increased risk on hepatic artery thrombosis, graft loss, and death in de novo liver transplant recipients. Because safety and efficacy of sirolimus as immunosuppressive therapy in liver transplant patients have not been established, such use is not recommended by the manufacturer.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sirolimus

vLess-DILI-concern

8

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

法規制情報

FDA Requirements · 1 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl sirolimus, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

安全データ

wgk
2
rtecs
VE6250000
ridadr
UN 1648 3 / PGII
毒性
LD50 in mice (mg/kg): 600 i.p.; >2,500 orally (Vézina)
hs_code
29349990
risk_code
36/38-36-20/21/22-11
hazard_code
Xi,Xn,F
safety_code
22-24/25-37/39-26-36/37-16
自然発火温度
301 °C
Hazard Classifications
Carc. 2Repr. 2
ストレージクラス
11 - Combustible Solids
有毒物質データの
53123-88-9(Hazardous Substances Data)

Sirolimus inhibits cytokine (Interleukin (IL)-2, IL-4, and IL-15) -- stimulated T lymphocyte activation and proliferation; it also inhibits antibody production. This may occur through formation of an immunosuppressive complex with FK Binding Protein-12 (FKBP-12). Although the sirolimus-(FKBP-12) complex is inactive against calcineurin activity, the complex binds to and inhibits activation of a key regulatory kinase, mammalian Target of Rapamycin (mTOR). This is believed to suppress cytokine-driven T-cell proliferation, inhibiting cell cycle progression from the G, to S phase.

Biological Half-Life · 2 件

The mean ± SD terminal elimination half-life (t½) of sirolimus after multiple dosing in stable renal transplant patients was estimated to be about 62 ± 16 hours.

The drug has an elimination half life of 57-63 hours in kidney transplant recipients.

Metabolism/Metabolites · 6 件

Sirolimus undergoes extensive metabolism in the intestinal wall and liver. Sirolimus is primarily metabolized by O-demethylation and/or hydroxylation via CYP3A4 to form seven major metabolites, including hydroxy, demethyl, and hydroxydemethyl metabolites, which are pharmacologically inactive. Sirolimus also undergoes counter-transport from enterocytes of the small intestine into the gut lumen.

Sirolimus is a substrate for both cytochrome P450 IIIA4 (CYP3A4) and P-glycoprotein. Sirolimus is extensively metabolized by O-demethylation and/or hydroxylation. Seven major metabolites, including hydroxy, demethyl, and hydroxydemethyl, are identifiable in whole blood. Some of these metabolites are also detectable in plasma, fecal, and urine samples. Glucuronide and sulfate conjugates are not present in any of the biologic matrices.

Biotransformation: Hepatic, extensive, by cytochrome p450 3A enzymes. Major metabolites include hydroxysirolimus, demethylsirolimus, and hydroxydemethyl-sirolimus.

... After incubation of sirolimus with human and pig small intestinal microsomes, five metabolites were detected using high performance liquid chromatography/electrospray-mass spectrometry: hydroxy, dihydroxy, trihydroxy, desmethyl and didesmethyl sirolimus. The same metabolites were generated by human liver microsomes and pig small intestinal mucosa in the Ussing chamber. Anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and erythromycin, inhibited small intestinal metabolism of sirolimus, confirming that, as in the liver, CYP3A enzymes are responsible for sirolimus metabolism in the small intestine. ...

Sirolimus has known human metabolites that include 16-O-Desmethylsirolimus, 39-O-Desmethylsirolimus, 24-Hydroxy-sirolimus, 11-Hydroxy-sirolimus, 25-Hydroxy-sirolimus, 46-Hydroxy-sirolimus, and 12-Hydroxy-sirolimus.

Half Life: 57-63 hours

FDA Pharmacological Classification · 6 件

W36ZG6FT64

SIROLIMUS

Physiologic Effects [PE] - Decreased Immunologic Activity

Established Pharmacologic Class [EPC] - mTOR Inhibitor Immunosuppressant

Mechanisms of Action [MoA] - mTOR Inhibitors

Established Pharmacologic Class [EPC] - Kinase Inhibitor

MeSH Pharmacological Classification · 4 件

Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.

Substances that inhibit the growth or reproduction of BACTERIA.

Absorption, Distribution and Excretion · 6 件

In adult renal transplant patients with low- to moderate-immunologic risk, oral administration of 2 mg sirolimus led to a Cmax of 14.4 ± 5.3 ng/mL for oral solution and 15.0 ± 4.9 ng/mL for oral tablets. The tmax was 2.1 ± 0.8 hours for oral solution and 3.5 ± 2.4 hours for oral tablets. In healthy subjects, the tmax is one hour. In a multi-dose study, steady-state was reached six days following repeated twice-daily administration without an initial loading dose, with the average trough concentration of sirolimus increased approximately 2- to 3-fold. It is suspected that a loading dose of three times the maintenance dose will provide near steady-state concentrations within one day in most patients. The systemic availability of sirolimus is approximately 14%. In healthy subjects, the mean bioavailability of sirolimus after administration of the tablet is approximately 27% higher relative to the solution. Sirolimus tablets are not bioequivalent to the solution; however, clinical equivalence has been demonstrated at the 2 mg dose level. Sirolimus concentrations, following the administration of Rapamune Oral Solution to stable renal transplant patients, are dose-proportional between 3 and 12 mg/m2.

Following oral administration of [<sup>14</sup>C] sirolimus in healthy subjects, about 91% of the radioactivity was recovered from feces and only 2.2% of the radioactivity was detected in urine. Some of the metabolites of sirolimus are also detectable in feces and urine.

The mean (± SD) blood-to-plasma ratio of sirolimus was 36 ± 18 L in stable renal allograft patients, indicating that sirolimus is extensively partitioned into formed blood elements. The mean volume of distribution (V<sub>ss/F</sub>) of sirolimus is 12 ± 8 L/kg.

In adult renal transplant patients with low- to moderate-immunologic risk, oral administration of 2 mg sirolimus led to oral clearance of 173 ± 50 mL/h/kg for oral solution and 139 ± 63 mL/h/kg for oral tablets.

Following administration of /Sirolimus/ Oral Solution, sirolimus is rapidly absorbed, with a mean time-to-peak concentration (t max ) of approximately 1 hour after a single dose in healthy subjects and approximately 2 hours after multiple oral doses in renal transplant recipients. The systemic availability of sirolimus was estimated to be approximately 14% after the administration of /Sirolimus/ Oral Solution. The mean bioavailability of sirolimus after administration of the tablet is about 27% higher relative to the oral solution.

In 22 healthy volunteers receiving Rapamune Oral Solution, a high-fat meal altered the bioavailability characteristics of sirolimus. Compared with fasting, a 34% decrease in the peak blood sirolimus concentration (C max ), a 3.5-fold increase in the time-to-peak concentration (t max ), and a 35% increase in total exposure (AUC) was observed. After administration of Rapamune Tablets and a high-fat meal in 24 healthy volunteers, C max , t max , and AUC showed increases of 65%, 32%, and 23%, respectively.

Tissue LocationsKidney
Cellular LocationsCytoplasm

用途と製造

Uses · 4 件

Triene macrolide antibiotic derived from Streptomyces hygroscopicus; Used in immunochemistry research and as a therapeutic immunosuppressant and antirestenotic (blocks reoccurrence of stenosis); [Merck Index]

Tool for immunochemistry.

Medication: Immunosuppressant

Used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. [Wikipedia]

Methods of ManufacturingTriene macrolide antibiotic isolated from Streptomyces hygroscopicus.
Formulations/Preparations · 3 件

Rapamune

Rapamycin

Oral: Solution 1mg/mL Rapamune (Wyeth). Tablets: 1 mg Rapamune (with povidone), (Wyeth); 2 mg Rapamune (with Povidone), (Wyeth).

General Manufacturing Information · 1 件

Information available in 2004 indicated that Sirolimus was used in the manufacture of pharmaceutical preparations in the following countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Mexico, New Zealand, Norway, Poland, Romania, Singapore, Spain, Sweden, Switzerland, Thailand, United Kingdom, USA (1,2)

応用分野 · 5 件

用途FK506 の構造類似体であ り、FK506 と同様に FK506 結合タンパク質 (FKBP)と結合しますが、FK506 とは異なり、 カルシニューリンの活性は阻害しません。ラ パマイシンと FKBP の複合体は mTOR に結 合し、mTOR のキナーゼ活性を阻害すること により、IL-2 からのシグナルを阻害します。

用途移植臓器拒絶の予防のため、リンパ脈管筋腫症の治療のために医学分野で使われている。ヒトにおいて免疫抑制機能を持ち、腎臓移植の拒絶の予防において特に有用である。インターロイキン-2(IL-2)の産生を低下させることによってT細胞およびB細胞の活性化を阻害する。冠動脈ステント(英語版)のコーティング剤としても使われている。

天然物の起源Rapamycin was first discovered in 1972 in the soil of Easter Island produced by a bacterium called Streptomyces hygroscopicus. It takes its name from Rapa Nui, the indigenous name for the island. It is known clinically as sirolimus or Rapamune.

使用Labelled Rapamycin. A triene macrolide antibiotic isolated from Streptomyces hygroscopicus. Name derived from the native word for Easter Island, RapaNui. Used as an immunosuppressant; antirestenotic. This compound contains aproximately 2% d0.;Labeled Sir

一般的な説明Rapamycin is an anti-fungal antibiotic isolated from Streptomyces hygroscopicus. This antibiotic is active against all strains of Candida albicans. It blocks the signal transduction pathways required for the activation of T-helper cells.

上流・下流製品情報

下流製品

メチルホスホン酸エチル40-O-[2-(t-butyldimethylsilyl)oxy]ethyl rapamycin

補足説明

定義ChEBI: A macrolide isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.